Dupilumab sustains efficacy despite LABA and ICS withdrawal in patients with asthma: a post hoc analysis

Michael Wechsler; Arnaud Bourdin; Klaus Rabe; Ian Pavord; J. Christian Virchow; Rohit Katial; Elliot Israel; Changming Xia; Olivier Ledanois; Mena Soliman; David Jackson

doi:10.1016/j.jaip.2026.04.010

Retour

Dupilumab sustains efficacy despite LABA and ICS withdrawal in patients with asthma: a post hoc analysis

Article de revue scientifique

Avec comité de lecture

Dupilumab sustains efficacy despite LABA and ICS withdrawal in patients with asthma: a post hoc analysis

Michael Wechsler, Arnaud Bourdin, Klaus Rabe, Ian Pavord, J. Christian Virchow, Rohit Katial, Elliot Israel, Changming Xia, Olivier Ledanois, Mena Soliman, …

Journal of Allergy and Clinical Immunology: In Practice

04/2026

DOI: https://doi.org/10.1016/j.jaip.2026.04.010

Fichiers et liens (1)

url

Find in HALAfficher

Indicateurs

1 Consultations de la notice

Détails

Titre: Dupilumab sustains efficacy despite LABA and ICS withdrawal in patients with asthma: a post hoc analysis
Créateurs - sans rôle: Michael Wechsler - National Jewish Health
Arnaud Bourdin - Université de Montpellier, PhyMedExp - Physiologie et Médecine Expérimentale du coeur et des muscles
Klaus Rabe - German Center for Lung Research
Ian Pavord - University of Oxford
J. Christian Virchow - University of Rostock
Rohit Katial - University of Colorado Denver
Elliot Israel - Brigham and Women's Hospital
Changming Xia - Regeneron (United States)
Olivier Ledanois - Sanofi (France)
Mena Soliman - Regeneron (United States)
David Jackson - Guy's Hospital
Détails de publication: Journal of Allergy and Clinical Immunology: In Practice
Identifiants: 99218109809311
Unité académique: PhyMedExp - Physiologie et Médecine Expérimentale du coeur et des muscles
Langue: Anglais
Type de ressource: Article de revue scientifique
Champs locaux: hal-05597875